Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Total Liabilities
Samsung Biologics Co Ltd
Total Liabilities Peer Comparison
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Total Liabilities
₩6.5T
|
CAGR 3-Years
53%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Total Liabilities
₩15.3B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Total Liabilities
₩290.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Total Liabilities
₩9.2B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Total Liabilities
₩41.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Total Liabilities
₩74B
|
CAGR 3-Years
175%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
See Also
What is Samsung Biologics Co Ltd's Total Liabilities?
Total Liabilities
6.5T
KRW
Based on the financial report for Mar 31, 2024, Samsung Biologics Co Ltd's Total Liabilities amounts to 6.5T KRW.
What is Samsung Biologics Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
30%
Over the last year, the Total Liabilities growth was -10%. The average annual Total Liabilities growth rates for Samsung Biologics Co Ltd have been 53% over the past three years , 30% over the past five years .